Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

LIPI-PROTECT-1 : Dietary Supplement in Subjects With Moderate Hypercholesterolemia (LPP1) (LPP1)

12 november 2026 uppdaterad av: Institut Pasteur de Lille

Effect of the Dietary Supplement LIPI-PROTECT-1 on Plasma LDL Cholesterol Concentration in Subjects With Moderate Hypercholesterolemia: A Pilot Study.

This is a multicenter, uncontrolled pilot study evaluating changes in plasma LDL-cholesterol (LDL-C) concentrations before and after 3 months of intake of the dietary supplement LIPI-PROTECT-1.

The main objective of this clinical trial is to evaluate the effect of LIPI-PROTECT-1 on plasma LDL-C concentration after 3 months of supplementation in participants with untreated moderate hypercholesterolemia.

A mean reduction in plasma LDL-C levels of approximately 14% (0.20 g/L) is expected after 3 months of supplementation.

The primary endpoint is the absolute (g/L) and relative (%) change in plasma LDL-C concentration between baseline and Month 3.

Studieöversikt

Status

Aktiv, inte rekryterande

Intervention / Behandling

Detaljerad beskrivning

Elevated low-density lipoprotein cholesterol (LDL-C) is an established risk factor for coronary cardiovascular disease. In individuals at low cardiovascular risk, lifestyle and dietary measures are recommended to reduce LDL-C levels and/or overall cardiovascular risk. Dietary supplements may be considered as part of these measures when their efficacy has been demonstrated.

LIPI-PROTECT-1 is a dietary supplement containing plant extracts and vitamins that may contribute to reducing plasma LDL-C levels. Some of its individual active ingredients have previously been investigated in clinical studies and have shown an LDL-C-lowering effect. However, the combination of these active ingredients has not previously been evaluated in a clinical study.

This pilot, multicenter, uncontrolled study is designed to provide preliminary estimates of the effect of LIPI-PROTECT-1 in adults with untreated moderate hypercholesterolemia.

A total of 20 men and women aged 18 to 65 years with untreated moderate hypercholesterolemia will be included. Participants will have an LDL-C level ≥1.5 g/L and a low cardiovascular risk. They will consume LIPI-PROTECT-1 for 3 months and will be required to maintain stable body weight, dietary habits, and physical activity throughout the study.

The primary objective is to assess the effect of LIPI-PROTECT-1 on plasma LDL-C concentration after 3 months of supplementation. The primary outcome will be the absolute and relative change in LDL-C concentration between baseline and Month 3. A mean reduction of approximately 14% (0.20 g/L) in LDL-C is expected after 3 months of supplementation.

Secondary objectives are to evaluate the effect of LIPI-PROTECT-1 after 1 and 3 months compared with baseline on body weight, body mass index, waist circumference, systolic and diastolic blood pressure, resting heart rate, fasting glucose, LDL-C, non-HDL cholesterol, total cholesterol, HDL cholesterol, triglycerides, LDL-C/HDL-C and total cholesterol/HDL-C ratios, and the atherogenic index (non-HDL-C/HDL-C).

Safety will also be assessed by comparing selected laboratory parameters between baseline and Month 3, including AST, ALT, gamma-glutamyl transferase, creatine kinase, lactate dehydrogenase, bilirubin, creatinine, and urea. Adherence to the dietary supplement will be assessed throughout the study.

Participants with high or very high cardiovascular risk, lipid-lowering treatment, diabetes, severe chronic diseases, or concomitant treatments likely to interfere with the assessment of efficacy or safety will be excluded.

Studietyp

Interventionell

Inskrivning (Faktisk)

20

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Nord
      • Lille, Nord, Frankrike, 59019
        • Prevention research center - Institut Pasteur de Lille
    • Vaucluse
      • Avignon, Vaucluse, Frankrike, 84140
        • Biophysium

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

- Men and women aged 18-65 years

For women :

If pre-menopausal: effective non-estrogenic* contraception initiated at least 2 cycles prior and maintained throughout the study If post-menopausal: not receiving estrogenic* Hormone Replacement Therapy (HRT)

  • LDL-cholesterol ≥ 1.5 g/L (calculated using the Friedewald formula)
  • Aware of their hypercholesterolemia and previously informed about the associated lifestyle and dietary measures
  • BMI between 20 and 35 kg/m² (inclusive)
  • Stable weight, dietary habits, and physical activity level for at least 3 months prior to the start of the study, with agreement to maintain them throughout the study
  • Willing to comply with study requirements
  • Signed informed consent

Exclusion Criteria:

  • Subjects receiving lipid-lowering or anti-dyslipidemic therapy (statins, ezetimibe, cholestyramine, fibrates, etc.)
  • Subjects with triglyceride levels > 4 g/L
  • Subjects requiring immediate lipid-lowering therapy
  • Subjects with diabetes (whether treated with medication or not, or diagnosed during the initial visit based on fasting blood glucose > 1.26 g/L)
  • Subjects receiving beta-blockers and/or diuretics
  • Subjects at high or very high cardiovascular risk according to ESC/EAS 2025 guidelines (assessed using the SCORE2 score, Appendix 2)
  • Subjects receiving anticoagulant therapy
  • Subjects receiving antiretroviral therapy
  • Subjects requiring immediate dietary intervention, or exhibiting fluctuating eating habits or an eating disorder (anorexia, bulimia, binge eating disorder)
  • Subjects on unstable treatment (initiated less than three months prior) or requiring the initiation of treatment during the study that, in the investigator's opinion, could interfere with the assessment of study endpoints (efficacy parameters: LDL, TG, HDL, blood glucose, blood pressure, weight; safety parameters: markers of hepatic, muscular, or renal function) Subjects who have consumed dietary supplements or functional foods capable of affecting cholesterol or triglyceride levels (phytosterols, phytostanols, red yeast rice, policosanols, beta-glucans at doses exceeding 3 g/day, artichoke or garlic extracts, probiotics, etc.) within the last 6 weeks
  • Subjects suffering from a severe chronic condition deemed incompatible with participation in the study by the investigator (serious digestive disorders, renal insufficiency, coronary artery disease, immunodeficiency, heart failure, rhythm disorders, active malignancy, hematological disease)
  • Subjects with an allergy to any of the components of LIPI-PROTECT-1
  • Pregnant or breastfeeding women, or women intending to become pregnant within the next 4 months
  • Subjects under legal protection (guardianship/curatorship, deprivation of liberty) or not covered by a social security scheme
  • Subjects participating in another clinical study or currently within the exclusion period of another study
  • Subjects whose condition is judged by the principal investigator or a qualified co-investigator deems that their health status or concomitant treatments are incompatible with the proper conduct of the clinical study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Food supplement group

Three tablets of LIPI-PROTECT-1 per day (1 at the end or after breakfast and 2 during dinner). Food supplements are consumed during 3 months by healthy volunteers

All subjects will consume 3 tablets per day during the entire intervention period, i.e. 12 weeks between V0 and V3, distributed as follows: 1 tablet in the morning at the end of or after breakfast (no taking on an empty stomach) and 2 tablets in the evening during dinner. If a dose is missed, 1 tablet can be taken at the next dose

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
To evaluate the effect of LIPI-PROTECT-1 on plasma LDL-cholesterol concentration (absolute value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia
Tidsram: To baseline at 3 months

To evaluate the absolute (g/L) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3).

To baseline at 3 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
To evaluate the effect of LIPI-PROTECT-1 on plasma LDL-cholesterol concentration (relative value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia.
Tidsram: To baseline at 3 months

To evaluate the relative (%) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3).

To baseline at 3 months
To evaluate the effect of LIPI-PROTECT-1 on LDL cholesterol.
Tidsram: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in LDL cholesterol in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on Non HDL cholesterol.
Tidsram: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in Non HDL cholesterol in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on total cholesterol.
Tidsram: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in total cholesterol in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on HDL cholesterol.
Tidsram: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in HDL cholesterol in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on triglycerides.
Tidsram: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on triglycerides in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on non HDL cholesterol/LDL (atherogenic index).
Tidsram: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non HDL cholesterol/LDL (atherogenic index) (ratio).

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on ratio LDL/HDL.
Tidsram: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non ratio LDL/HDL (ratio).

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on ratio total cholesterol/HDL.
Tidsram: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on ratio total cholesterol/HDL (ratio).

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on fasting blood glucose levels.
Tidsram: At baseline, 1 month and 3 months

Variation in fasting blood glucose (unit: g/l) between VS, V1, and V3

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on weight.
Tidsram: At baseline, 1 month and 3 months

Changes in weight (unit : kilograms) between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on Body Mass Index (BMI).
Tidsram: At baseline, 1 month and 3 months

Changes in BMI (weight and height will be combined to report BMI) in kg/m^2between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on waist circumference.
Tidsram: At baseline, 1 month and 3 months

Changes in waist circumference (unit: cm) between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on arterial blood pressure
Tidsram: At baseline, 1 month and 3 months

Variation in systolic blood pressure and diastolic blood pressure (unit: mm Hg) between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-1 on heart rate
Tidsram: At baseline, 1 month and 3 months

Variation in Heart rate (unit: Pul/min) between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the safety of LIPI-PROTECT-1 on hepatic metabolism: ASAT/ALAT, GGT
Tidsram: At baseline, 1 month and 3 months

Changes in safety biomarkers : ASAT/ALAT and GGT(unit: UI/l) between baseline and V3 .

At baseline, 1 month and 3 months
To evaluate the safety of LIPI-PROTECT-1 on hepatic metabolism : Creatinine, bilirubin
Tidsram: At baseline and 3 months

Changes in safety biomarkers : Creatinine, bilirubin (unit: mg/dl) between baseline and V3.

At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-1 on renal metabolism : Urea
Tidsram: At baseline and 3 months

Changes in safety biomarkers : Urea (unit: mg/dl) between baseline and V3.

At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-1 on renal metabolism : Creatinine Phophoskinase (CPK)
Tidsram: At baseline and 3 months

Changes in safety biomarkers : CPK (unit : UI/l) between baseline and V3.

At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-1 on Renal metabolism : Lactate Deshydrogenase (LDH)
Tidsram: At baseline and 3 months

Changes in safety biomarkers : LDH (unit : UI/l) between baseline and V3.

At baseline and 3 months
To assess adherence to LIPI-PROTECT-1 consumption by pillbox weighing
Tidsram: At baseline, 1 month and 3 months

Adherence assessed by weighing the pillbox at each visit and comparing the weight with the initial weight recorded at baseline (V0).

At baseline, 1 month and 3 months
To assess self-reported adherence to LIPI-PROTECT-1 consumption
Tidsram: At 1 month, 2 months and 3 months

Adherence assessed through participant self-reporting of supplement consumption and missed doses.

At 1 month, 2 months and 3 months
To assess adherence to LIPI-PROTECT-1 consumption by counting returned tablets
Tidsram: At 3 months

Adherence assessed by counting the remaining tablets returned by participants at the end of the study.

At 3 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studiestol: Coralie Berthier, PhD, Institut Pasteur de Lille

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

18 september 2026

Primärt slutförande (Beräknad)

31 januari 2027

Avslutad studie (Beräknad)

30 mars 2027

Studieregistreringsdatum

Först inskickad

3 november 2026

Först inskickad som uppfyllde QC-kriterierna

12 november 2026

Första postat (Faktisk)

18 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera